Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Recent and future changes in the landscape of AML: the addition of venetoclax and MRD eradication

Farhad Ravandi • 15 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Venetoclax

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses recent and future areas of interest in the treatment of acute myeloid leukemia (AML), including the addition of venetoclax to other treatment regimens to improve response, and the use of measurable residual disease (MRD) as a measure of treatment efficacy and a surrogate endpoint in clinical trials. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Research funding: Astex/Taiho.

More from Farhad Ravandi

Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
2:04
Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
Farhad Ravandi • 21 Sep 2026
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
1:40
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
Farhad Ravandi • 21 Sep 2026
Will MRD eradication become a routine treatment goal in AML?
1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
2:18
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
Farhad Ravandi • 21 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals